Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

Key Inclusion Criteria:

• Has a body mass index between 18 and 32 kg/m2, inclusive
• Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed at screening and/or prior to administration of initial dose of study drug
• Is in good health based on laboratory safety testing obtained at the screening visit, as described in the protocol
• Normal aPTT, normal PT, and normal platelet counts at screening period and at day -1 as defined by the local laboratory
• Hemoglobin values at screening period and at day -1 as described in the protocol

Key Exclusion Criteria:

• History of any major surgical procedure or clinically significant physical trauma, in the opinion of the investigator, that may pose a risk to the participant by study participation
• Whole blood donation within the previous 56 days or plasma donation within the previous 7 days prior to screening
• History of clinically significant bleeding, requiring hospitalization or blood products, that in the opinion of the investigator may pose a risk to the participant by study participation
• History of bleeding diathesis as described in the protocol
• Members of the clinical site study team and/or his/her immediate family, unless prior approval granted by the sponsor
• Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study

NOTE: Other protocol-defined inclusion/exclusion criteria apply